Photopharmacology

Velema, Wim

Publication date:
2014

Citation for published version (APA):
Velema, W. (2014). *Photopharmacology*. University of Groningen.

Chapter 2

Design, Synthesis and Inhibitory Activity of Potent, Photoswitchable Mast Cell Activation Inhibitors

Willem A. Velema[1], Marco van der Toorn[2], Wiktor Szymanski[1,3] and Ben L. Feringa[1]

Allergic reactions affect millions of people worldwide. The need for new and effective anti-allergic agents is evident and insight into the underlying mechanisms that lead to allergic events is necessary. In this chapter, the design, synthesis and activity of photoswitchable mast cell activation inhibitors is reported. In mast cell degranulation assays, these inhibitors possess significantly greater potency than an original, chromone-based anti-allergic agent. Furthermore, one of the photoswitchable inhibitors shows a substantial difference in inhibitory activity between its two photoisomeric forms. Further optimization could ultimately lead to a photoswitchable compound suitable for studying mechanisms involved in allergic reactions in a novel manner, with activity addressable by light and with precise spatiotemporal control over events at the molecular level.

[1]Stratingh Institute for Chemistry, University of Groningen, Groningen, The Netherlands. [2]Laboratory of Allergology and Pulmonary Diseases, Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands. [3]Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

2.1 Introduction

The prevalence of allergic diseases has increased over the last decades[1,2] and the search for suitable pharmacotherapeutical treatment is ongoing.[3,4] Several options to treat allergies are available,[5] including antihistamines, leukotriene inhibitors, corticoids and chromones. This last class of drugs has lost popularity, mainly due to their less pronounced effect and short duration of action.[6] However, chromones show few side-effects,[6] as opposed to the commonly used corticoids,[7,8] which renders them continuously interesting therapeutic agents. Furthermore, they seem to have an interesting, yet not fully understood, mechanism of action.[9]

Chromones stabilize mast cells,[10] which are effector cells of immediate hypersensitivity reactions and therefore play a key role in allergic diseases. These cells can be found throughout the human body and they secrete granules upon activation.[11,12] The granules contain inflammatory mediators, which induce the symptoms of an allergic reaction, like edema, warmth and itchiness.[11] Activation of mast cells occurs as a result of cross-linking of high affinity IgE receptors on the cell surface by allergens.[13] Chromones bind to the Cromolyn Binding Protein (CBP) on the surface of mast cells and inhibit this activation process.[14] While the exact mechanism of their action is yet to be elucidated, and other targets have been proposed, it is hypothesized that chromones interfere with the calcium influx, which is necessary for degranulation.[15,16]

Our aim was to design and synthesize a new class of chromone derivatives, which have higher potency than the available, chromone-based drugs, such as DiSodiumCromoGlycate[17] (DSCG, Fig. 2.1A). DSCG inhibits mast-cell activation and its structure-activity relationships are well studied.[18] The drug is a dimeric ligand and consists of two chromone moieties linked by a spacer (Fig. 2.1A). Altering the length of the spacer changes the inhibitory activity of the drug.[18,19] However, we anticipated that the molecular structure of the spacer, rather than length only, might also influence the drugs' activity as was shown for example before for opioid receptor antagonists.[19] To investigate this, three different DSCG derivatives were designed with an azobenzene photoswitch as a spacer (Fig. 2.1A). Azobenzene molecules can be photoisomerized, changing the molecule's length, dipole moment and geometry in a reversible manner.[20] In addition, their structure is essentially different from that of the spacer of DSCG. This allows studying the influence of both the structure and the length of the spacer on inhibitory activity of the drug. Moreover, incorporating a photoswitch into the DSCG molecule might allow changing its inhibitory potency

upon light-irradiation. This eventually could lead to optical control over mast cell activation with high spatiotemporal resolution, as was shown with other bioactive compounds.[21,22] The information gained from these experiments could provide more insight into the mechanisms by which DSCG inhibits mast cell activation and the way it interacts with the CBP.

In this chapter we describe the design and synthesis of three analogs of DSCG, with an azobenzene photoswitch incorporated in their structure. The inhibitory capacity of the molecules, named Di-AzoChromone (DAC), *Meta*-AzoChromone (MAC) and *Para*-AzoChromone (PAC) (Figure 2.1A), in both photo-isomeric forms, was tested on human mast cell cultures. Remarkably, the molecules showed to have a considerably higher inhibitory effect on an evoked degranulation in mast cell cultures, as compared to the common drug DSCG. Furthermore, PAC showed a significant difference in inhibitory capacity in two isomeric forms. It is anticipated that external control of mast cell activation can be achieved by switching between the two forms with light

2.2   Results

2.2.1 Design of photoswitchable inhibitors

The structure of photoswitchable inhibitors DAC, MAC and PAC was inspired by the known mast cell activation inhibitor DSCG. This drug consists of two chromone groups linked by a spacer (Fig. 2.1A). The length of the spacer influences the inhibitory activity of the drug.[18] We chose an azobenzene unit as the photoswitch to connect the chromone units, since the difference in structure and length between the two forms (the *trans* and *cis* isomer) of this photoswitch is well-defined and relatively large.[20,23] Azobenzenes are privileged photoswitches for usage in bio-active compounds due to their small size and stability in aqueous environments.[20]

We hypothesized that both chromone groups need to bind to the CBP for the drug to have an optimal inhibitory effect (Figure 2.1B), as was shown for other bivalent compounds.[24,25] With this in mind, we designed three photoswitchable inhibitors called DAC, MAC and PAC (Fig. 2.1A). The first photoswitchable inhibitor, DAC, was designed in such a way that the azobenzene photoswitch integrates two chromone groups in its structure. This reduced the length of the spacer, as compared to DSCG, and rendered the molecule more rigid, which could result in a larger difference in inhibitory activity between the two photoisomeric forms. Compounds MAC and PAC (Figure 2.1A) consist of an azobenzene moiety with two chromone groups linked to it in the *meta* and *para* positions, respectively. A methylene group was placed in-

between the azobenzene and chromone groups to introduce more flexibility in the molecule. This flexibility might be favorable when two chromone groups need to interact with the CBP at the same time (Fig. 1B).


Figure 2.1 *Principle and molecular structure of photoswitchable mast cell activation inhibitors. (A) Molecular structure of the mast cell activation inhibitor DiSodiumCromoglycate (DSCG) and the three designed photoswitchable inhibitors MAC, PAC and DAC. (B) Envisioned mode of action of MAC and PAC. When two chromone groups (illustrated as spheres) of the inhibitor in one of the photoisomeric forms are bound to the cromolyn binding protein (CBP), mast cell activation is inhibited. When the molecule photoisomerizes to the other form, only one chromone group can bind and mast cell activation is not inhibited.*

2.2.2 Synthesis

The photoswitchable inhibitor DAC was synthesized starting from chromone ethyl ester (**1**) (Scheme 2.1), which was obtained from hydroxyacetophenone and diethyl oxalate.[26] Compound **1** was converted into nitroso-chromone **4** via sequential nitration,[27] reduction[27] and oxidation reactions. Azobenzene formation from precursors **3** and **4**, followed by a saponification step, afforded the photoswitchable inhibitor DAC (**6**).

Compounds MAC and PAC were prepared in six steps as depicted in Scheme 2.2. The key features of these syntheses include a formation of a diazo compound by a reaction between *m/p*-toluidine and *m/p*-nitrosotoluene (**8a** and **8b**) to afford methylated azobenzenes (**9a** and **9b**), which were subjected to radical bromination to

yield compound **10a** and **10b**. *Via* a double Williamson ether formation, 5-hydroxychromone methyl ester **7**, obtained from 1,2-dihydroxyacetophenone and dimethyl oxalate,[28] was introduced to both methylene groups of the azobenzenes **10a** and **10b** resulting in **11a** and **11b**. A saponification step afforded the sodium salts of the photoswitchable inhibitors MAC (**12a**) and PAC (**12b**).

Scheme 2.1[a]

[a]*Reagents and conditions: (i) diethyl oxalate, NaOEt/EtOH, H_2SO_4 (75%); (ii) H_2SO_4, HNO_3, rt, 1 h (81%); (iii) H_2, Pd/C, benzene, rt, 16 h (75%); (iv) Oxone, DCM/water, rt, 2 h (70%); (v) compound **3**, glacial AcOH, rt, 2 d (43%); (vi) EtOH, NaOH, reflux, 2 h (91%).*

Scheme 2.2[a]

[a]*Reagents and conditions: (i) dimethyl oxalate, NaOMe/MeOH, HCl (33%); (ii) Oxone, DCM/water, rt, 1 h (**8a**: 54%; **8b**: 25%); (iii) m/p-toluidine, glacial AcOH, rt, 16 h (**9a**: 55%; **9b**: 86%); (iv) NBS, AIBN, CCl_4, reflux, 16 h (**10a**: 35%; **10b**: 42%); (v) Cs_2CO_3, MeCN, reflux, 5 h (**11a**: 70%; **11b**: 35%); (vi) EtOH, NaOH, reflux, 2 h (**12a**: 86%; **12b**: 91%).*

2.2.3 Photoswitchable behavior of designed mast cell activation inhibitors

The photoswitchable behavior of DAC, MAC and PAC was studied using UV-VIS spectroscopy and RP-HPLC. The *trans*-isomers of DAC, MAC and PAC have a characteristic absorbance maximum between 300 and 400 nm in water. This absorbance maximum decreases when the molecules are photoswitched to their *cis*-isomers and a new absorbance maximum appears around 430 nm (Fig. 2.2A-C).[29] Using RP-HPLC, the ratio of photoisomers was determined for both the non-irradiated and 365 nm-irradiated forms of DAC, MAC and PAC (Table 2.1). Higher photostationary states were obtained when the photoswitchable inhibitors were irradiated with 365 nm light in DMSO as compared to water (Table 2.1). Therefore, for inhibitory activity studies (*vide infra*), the compounds were switched at a high concentration in DMSO and diluted in water to obtain a maximum concentration of 1% DMSO (v/v). The inhibitors could be photoisomerized by alternating irradiation at 365 nm and 400-700 nm, for at least 5 times showing little fatigue (Fig. 2.2D-F). Thermal *cis-trans* isomerization was relatively slow at 37 °C (t½ ≥ 3 hours for all compounds) (Fig. 2.2G-I). Since in the inhibitory activity studies (*vide infra*) the incubation times were only 30 min, assaying the activity of the *cis*-form without significant *cis-trans* conversion was possible.

Figure 2.2 *Photochemical properties of compound DAC, MAC and PAC. (A-C) UV-Vis absorption spectra of DAC (125 µM), MAC (128 µM) and PAC (100 µM) in water. The solid lines represent the spectra of the non-irradiated forms and the dashed lines of the 365 nm irradiated forms. (D-F) Reversible photochromism of photoswitchable inhibitors. (G-I) Thermal cis-trans isomerization at 37 °C.*

Table 2.1 *Ratio of trans and cis isomers of the photoswitchable inhibitors under different conditions. Ratios are determined at the isosbestic point (405 nm for DAC, 270 nm for MAC, 270 nm for PAC) with RP-HPLC (C18, flow 1 mL/min, MeCN and H_3PO_4, pH=3.0).*

	DAC (*trans:cis*)	**MAC** (*trans:cis*)	**PAC** (*trans:cis*)
Non-Irradiated	99:1	88:12	91:9
Irradiated (water)	59:41	45:55	56:44
Irradiated (DMSO)	48:52	38:62	19:81

2.2.4 Inhibitory activity

The inhibitory activity of DAC, MAC and PAC was determined on the LAD2[30] mast cell line using a β-hexosaminidase release assay.[31] β-Hexosaminidase is an enzyme that is secreted by mast cells upon activation and therefore its activity is a reliable measure for the degree of mast cell degranulation.[32] LAD2 cells were incubated with different concentrations of DSCG and non-irradiated DAC, MAC and PAC for 30 min, after which degranulation was evoked by the secretagogue Compound 48/80.[33] From Fig. 2.3A, it is apparent that DAC, MAC and PAC show significantly greater inhibitory activity than the original drug DSCG. MAC and PAC seem to have an almost 100 times greater inhibitory potency than DSCG. Furthermore, MAC and DAC show greater efficacy than PAC.

At the concentration of Compound 48/80 (1.0 µM) that was used in this assay, DSCG did not show any inhibitory activity. At lower concentrations of Compound 48/80 (0.1 µM), DSCG was able to inhibit mast cell degranulation (Fig. 2.3B), albeit with lower activity than MAC (~100 times).


Figure 2.3   *Concentration-response curves of mast cell activation inhibitors (n=3). (A) Degranulation was evoked by 1.0 µg/mL of Compound 48/80. The mast cell activation inhibitors MAC and PAC show inhibitory activity in the same concentration range with IC_{50} values of 10 µM and 28 µM, respectively. DAC shows to be a less potent inhibitor with an IC_{50} value of 272 µM, but is still more potent than the original drug DSCG, which did not show any inhibitory activity under these conditions ($IC_{50} > 1$ mM). MAC and DAC show higher efficacy than PAC. (B) Inhibitory activity of MAC and DSCG. Degranulation was evoked by 0.1 µg/mL of Compound 48/80. MAC shows inhibition at a concentration of 10 µM whereas DSCG shows inhibition at a concentration of 1000 µM.*

The inhibitory activity of the most potent inhibitor, MAC, was further investigated using a different method, assaying histamine release[34] (Fig. 2.4). LAD2 cells were incubated with different concentrations of DSCG and MAC for 30 min, after which a degranulation was evoked by Compound 48/80. At the assayed concentrations, DSCG did not show any inhibitory activity, whereas MAC completely inhibited histamine release at a concentration of 100 μM.


Figure 2.4   *Histamine release assay of MAC and DSCG (n=3). Degranulation was evoked by 1.0 μg/mL of Compound 48/80. MAC completely inhibited histamine release at a concentration of 100 μM. The fluorescence detected was comparable to the control measurement without Compound 48/80. DSCG did not show any inhibitory activity at the studied concentrations.*

Next, the difference in inhibitory activity between the two photoisomers of DAC, MAC and PAC was determined. The inhibitory activity was measured for each compound at two concentrations that were on the steep part of the concentration-response curve, because at these concentrations a possible difference in inhibitory activity is most pronounced. LAD2 cells were incubated with either non-irradiated solutions of DAC, MAC and PAC or with solutions that were irradiated with 365 nm light prior to incubation. The photoswitched samples were irradiated in DMSO and diluted in water to obtain a maximum concentration of 1% DMSO (v/v). After evoking a degranulation with Compound 48/80, β-hexosaminidase release was determined (Fig. 2.5). We observed no significant difference in inhibitory activity between the

irradiated and non-irradiated forms of MAC and DAC. However, a significant difference was observed between the irradiated and non-irradiated form of PAC. At a concentration of 10 µM, the relative difference in inhibitory activity between the two forms of PAC is 25%. The non-irradiated form, which consists of 91% *trans*-PAC in the photostationary state (PSS), is more active than the irradiated form which is 81% *cis*-PAC in the PSS.


Figure 2.5 *Inhibitory activity of the non-irradiated and 365 nm light-irradiated forms of MAC, PAC and DAC. (A, B) No difference between the two forms of DAC and MAC were observed. (C) A difference in activity was observed between the two forms of PAC. Non-irradiated PAC was 25% more active than irradiated PAC at a concentration of 10 µM.*

2.3   Discussion

The chromone-based drugs are an attractive and routinely used class of anti-allergic agents, because of their mast-cell stabilizing capability and the limited side effects.[6] The main disadvantage of this class of drugs is its low effectiveness.[35] The novel, azobenzene bridged, bis-chromone compounds MAC and PAC show an almost 100 times higher potency than the chromone drug DSCG, basing on β-hexosaminidase release assays (Fig. 2.3). This large increase in potency makes MAC and PAC interesting potential anti-allergic agents, especially if the side effect pattern remains unchanged. Further investigation is ongoing to determine the toxicity and side effects of these compounds.

In earlier research by Hunter *et al.*, the effect of the length of the spacer between the two chromone groups on inhibitory activity was explored.[18] Inhibitors containing longer spacers, existing of alkylene chains, showed a decrease in activity when the spacer exceeded 6 atoms.[18] Spacer length is known to modulate selectivity in bivalent ligands.[19] Our results suggest that the length of the spacer plays a role in the inhibitory activity, since there is a change in activity between the two isomeric forms of PAC, which have a distinct difference in distance between the chromone units. However, our results also suggest that the molecular structure of the spacer, rather than spacer length only, might be of great importance for activity. Similar observations have already been reported earlier for opioid receptor antagonists.[19] MAC and PAC include an azobenzene group as a spacer which might be considered lengthy compared to the original linker in DSCG and showed to be almost 100 times more potent than the model compound DSCG in a degranulation assay based on the activity of β-hexosaminidase, released from granules.

To exclude the false positive result, which could stem from the inhibition of β-hexosaminidase activity by MAC, we also assayed the amount of histamine released from the granules. The results obtained in this experiment confirmed the much higher activity of MAC in stabilizing mast cell activation, as compared to DSCG.

Several modes of actions for chromones have been proposed, apart from CBP binding, including the blockage of chloride channels[36] and G-Protein-Coupled-Receptor 35 binding.[37] It is possible that the newly designed inhibitors exhibit an effect via binding to multiple receptor types, which makes it harder to explain the effect of changes in molecular structure on activity. For instance, the effect via binding to various receptor types could provide an explanation for the observed lower efficacy of PAC, as compared to DAC, MAC and DSCG.

The lack of difference in inhibitory activity between the two forms of MAC, which differ significantly in length, also confirms our observation that the structure and geometry of the spacer, rather than its length, is important for the interaction between mast cell activation inhibitors and the CBP.

Since there is a difference in inhibitory activity between the *cis* and *trans* isomer of PAC, this photoswitchable inhibitor might be a useful tool to study the events involved in mast cell degranulation. To completely control the state of mast cell activation as an 'on/off' event, it is necessary to enhance the difference in activity between the irradiated and non-irradiated forms of a photoswitchable inhibitor. To achieve this, first the PSS of the least active isomer should be optimized. In case of PAC, the least active isomer is the *cis* form. The PSS of irradiated PAC consists of 81% *cis* and 19% *trans*. This means that when PAC is photoisomerized, still 19% of the more potent isomer is present. If this percentage can be reduced, a larger difference in activity would be obtained. One possibility to achieve this is the use of bidirectional azobenzenes, that can switch between ≈100% *trans* and ≈100% *cis* isomer.[38–41] In this class of azobenzenes the UV/Vis absorption maxima of the *trans* and *cis* form do not overlap, which allows better control over photoisomerization and results in a high PSS for both forms. Secondly, the optimal distance between the two chromone groups in the molecular structure of the inhibitor needs to be investigated. Then a photoswitchable inhibitor could be designed with maximum activity in one photoisomeric form and minimum activity in the other form.

2.4   Conclusions

Three photoswitchable mast cell activation inhibitors have been designed and synthesized. All three inhibitors are more potent than the commercially available drug DSCG. Especially the compounds MAC and PAC show a large increase in potency when compared to DSCG, which renders them interesting candidates for anti-allergic agents. Our results suggest that the molecular structure of the spacer connecting the two chromone groups is of great importance for activity. Furthermore, a difference in inhibitory activity was observed between the non-irradiated and irradiated form of PAC. This result comprises the first step on the way to our far reaching goal, i.e. obtaining complete control over mast cell activation with light. In addition, our results show how molecular photoswitches can be used to study and interfere, in a non-invasive manner, with biological processes and how they might be used as a tool in chemical biology.

2.5 Experimental section

2.5.1 LAD2 Cell culture

The human mast cell line LAD2 was kindly provided by Dr. A. Kirshenbaum (National Institute of Allergy and Infectious Diseases, Bethesda, MD). LAD2 cells were cultured in suspension at 37 °C, 95% relative humidity and 5% CO_2 in StemPro-34 Serum-free medium (Invitrogen) supplemented with 2 mM L-glutamine (Sigma Aldrich), 100 IU/mL penicillin (Sigma Aldrich), 100 μg/mL streptomycin (Sigma Aldrich) and 100 ng/ml rhSCF (Invitrogen). Cells were not allowed to grow beyond a density of 5.0 x 10^5 cells/mL and fresh medium was supplied once a week.

2.5.2 β-Hexosaminidase Assay

β-Hexosaminidase release was measured according to a previously published method.[32] In short, 50 μL of supernatant was transferred to a 96-well plate. To this 100 μL of a 2 mg/mL solution of *p*-nitrophenyl-*N*-acetyl-D-glucosaminidine in citrate buffer pH 4.5 was added. The plate was incubated at 37 °C for 1 h. The reaction was stopped by adding 100 μL of 0.4 M glycine solution and the absorbance was measured on a fluorescent plate reader at a wavelength of 405 nm. Subsequently, the percentage released β-hexosaminidase was determined by comparison with the absorption of cell lysate of the same cells using the following formula:

$$\frac{supernatant}{supernatant+lysate} \ x \ 100\% = \% \ Released \ \beta-Hexosaminidase.$$

2.5.3 Histamine assay

Histamine release was measured according to a previously published method.[34] In short, 80 μL of supernatant was transferred to a 96-well plate. To this 20 μL of a 1M aqueous NaOH solution was added. Next, 20 μL of an 0.25% *o*-phthalaldehyde in MeOH was added and followed by incubation for 4 min at room temperature. Then 10 μL of a 3M aqueous HCl solution was added and the fluorescence was measured on a fluorescent plate reader (λ_{ex}= 360 nm, λ_{em}= 450 nm).

2.5.4 Inhibitory Activity Tests

LAD2 cells were suspended in HEPES buffer at a concentration of 50,000 cells/mL for the β-hexosaminidase release assay and 1,000,000 cells/mL for the histamine release assay. 80 μL of cell suspension was transferred to a microreaction cup, to which 10 μL of inhibitor solution was added. This was incubated at 37 °C for 30 min, after which

10 µL of a Compound 48/80 solution was added. Next, the cell suspension was incubated for 30 min at 37 °C and β-hexosaminidase or histamine release was assayed.

2.5.5 Photoswitching Experiments

Irradiation experiments were performed with a spectroline ENB-280C/FE UV lamp (365 nm) and Thor Labs OSL1-EC Fiber Illuminator (white light).

2.5.6 Synthesis

2.5.6.1 General Information

For synthesis, all chemicals were obtained from commercial sources and used as received unless stated otherwise. Solvents were reagent grade. Thin-layer chromatography (TLC) was performed using commercial Kieselgel 60, F254 silica gel plates. Flash chromatography was performed on silica gel (Silicycle Siliaflash P60, 40-63 µm, 230-400 mesh). Drying of solutions was performed with $MgSO_4$ and solvents were removed with a rotary evaporator. Chemical shifts for NMR measurements were determined relative to the residual solvent peaks (δ_H 7.26 for $CHCl_3$ and 2.50 for DMSO, δ_C 77.16 for $CDCl_3$ and 39.52 for DMSO). The following abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; brs, broad signal; appt, apparent triplet. HRMS (ESI) spectra were obtained on a Thermo scientific LTQ Orbitrap XL. Melting points were recorded using a Buchi melting point B-545 apparatus. UV/Vis absorption spectra were recorded on an Agilent 8453 UV-Visible Spectrophotometer using Uvasol grade solvents. All compounds whose IC_{50} values were determined had purities ≥ 95%. Purities were determined with analytical RP-HPLC performed on a JASCO PU-980 chromatography system using a GRACE Alltima HP C18 5µ column. Compounds were detected with a JASCO UV-1575 UV-Vis intelligent detector.

2.5.6.2 Synthesis of DAC

### Ethyl 4-oxo-4H-chromene-2-carboxylate (1)

2-Hydroxyacetophenone (2.04 g, 15 mmol) and diethyl oxalate (5.12 g, 35 mmol) were dissolved in ethanol (10 mL) and added to a solution of sodium (1.49 g, 65 mmol) in ethanol (100 mL). The reaction mixture was heated at reflux for 1 h, after which it was cooled down and acidified with concentrated HCl until a white precipitate was formed. The precipitate was filtered off and the filtrate was concentrated and extracted with ethyl acetate, washed with brine and dried (MgSO$_4$). After evaporation a solid was obtained, which was recrystallized from methanol/di*iso*propylether (4:1) to yield 2.45 g (75%) of a white solid. Mp. 66-68°C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 8.21 (dd, J = 7.9, 1.7 Hz, 1H), 7.75 (ddd, J = 8.7, 7.1, 1.7 Hz, 1H), 7.62 (dd, J = 8.6, 1.0 Hz, 1H), 7.46 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.12 (s, 1H), 4.47 (q, J = 7.1 Hz, 4H), 1.41 (t, J = 7.2 Hz, 3H). ^{1}H-NMR spectrum in agreement with published data.[26]

Ethyl 6-nitro-4-oxo-4H-chromene-2-carboxylate (2)

Compound **1** (200 mg, 0.92 mmol) was suspended in 65% nitric acid (0.12 mL) and the mixture was cooled on ice. Concentrated sulfuric acid (1.5 mL) was added and the mixture was stirred for 2 h at room temperature, poured on ice-cooled water and the formed precipitate was filtered off to yield 195 mg (81%) of a white solid. Mp. 178-179 °C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 9.07 (d, J = 2.8 Hz, 1H), 8.57 (dd, J = 9.2, 2.8 Hz, 1H), 7.78 (d, J = 9.2 Hz, 1H), 7.19 (s, 1H), 4.50 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.1 Hz, 3H).
^{13}C-NMR (100 MHz, CDCl$_3$): δ 176.8, 159.7, 158.7, 152.8, 145.2, 128.9, 124.4, 122.5, 120.6, 115.0, 63.5, 14.1.
HR-MS (ESI, [M+H]$^+$): Calcd. for C$_{12}$H$_{10}$NO$_6$: 264.0508; Found: 264.0502.

Ethyl 6-amino-4-oxo-4H-chromene-2-carboxylate (3)

Compound **2** (300 mg, 1.14 mmol) was dissolved in benzene (100 mL) and stirred overnight with 10% palladium on charcoal (15 mg) under a hydrogen atmosphere (balloon) at room temperature. The mixture was filtered over

celite. The filtrate was evaporated yielding 300 mg of orange needles. Mp. 177-178 °C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.45 (d, J = 9.0 Hz, 1H), 7.35 (d, J = 2.9 Hz, 1H), 7.11 – 7.03 (m, 2H), 4.45 (q, J = 7.1 Hz, 2H), 3.92 (brs, 2H), 1.43 (t, J = 7.1 Hz, 3H).

^{13}C-NMR (100 MHz, CDCl$_3$): δ 178.4, 160.8, 151.7, 149.6, 144.6, 125.4, 123.2, 119.8, 113.6, 107.4, 62.8, 14.1.

HR-MS (ESI, [M+H]$^+$): Calcd. for C$_{12}$H$_{12}$NO$_4$: 234.0766; Found: 234.0762.

Ethyl 6-nitroso-4-oxo-4H-chromene-2-carboxylate (4)

Compound **3** (100 mg, 0.43 mmol) was dissolved in DCM (2 mL), a solution of oxone (422 mg, 0.69 mmol) in H$_2$O (8 mL) was added and the biphasic mixture was stirred at room temperature for 2 h. The organic layer was separated and the aqueous layer was extracted twice with DCM. The combined organic layers were washed with 1 M aq. HCl, saturated NaHCO$_3$ and brine and dried (MgSO$_4$). Evaporation of the solvent yielded 75 mg (70%) of a green solid. Mp. 144-145 °C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 9.31 (d, J = 2.1 Hz, 1H), 7.77 – 7.65 (m, 2H), 7.21 (s, 1H), 4.50 (q, J = 7.1 Hz, 2H), 1.46 (t, J = 7.1 Hz, 3H).

^{13}C-NMR (100 MHz, CDCl$_3$): δ 177.9, 161.6, 159.9, 159.2, 152.6, 125.6, 124.9, 120.8, 120.2, 115.0, 63.4, 14.1.

HR-MS (ESI, [M+H]$^+$): Calcd. for C$_{12}$H$_{10}$NO$_5$: 248.0559; Found: 248.0552.

Diethyl 6,6'-(diazene-1,2-diyl)bis(4-oxo-4H-chromene-2-carboxylate)

(5) Compounds **3** (70.8 mg, 0.304 mmol) and **4** (75.0 mg, 0.304 mmol) were

dissolved in glacial acetic acid (2.5 mL) and the mixture was stirred for 2 d. The solution was diluted with water and extracted with DCM. The organic phase was washed with water (4x) and brine and dried (MgSO$_4$). Recrystallization from DCM yielded 60 mg (43%) of a light orange solid. Mp. 254-255 °C (dec.).

^{1}H-NMR (400 MHz, CDCl$_3$): δ 8.79 (d, J = 2.4 Hz, 2H), 8.35 (dd, J = 9.0, 2.4 Hz, 2H), 7.77 (d, J = 9.0 Hz, 2H), 7.18 (s, 2H), 4.50 (q, J = 7.2 Hz, 4H), 1.46 (t, J = 7.1 Hz, 6H).

^{13}C-NMR (100 MHz, CDCl$_3$): δ 178.1, 160.3, 157.5, 152.4, 149.4, 127.2, 125.0, 122.8, 120.2, 114.9, 63.2, 14.1.

HR-MS (ESI, [M+H]$^+$): Calcd. for C$_{25}$H$_{18}$N$_2$O$_8$: 463.1136 ; Found: 463.1131.

Sodium (E)-6,6'-(diazene-1,2-diyl)bis(4-oxo-4H-chromene-2-carboxylate) (6) (DAC) To a solution of compound **5** (50 mg, 0.11 mmol) in

ethanol (2 mL) was added aq. NaOH (2.5 M, 0.128 mL) dropwise at 0 °C. The reaction mixture was heated at reflux for 2 h after which the insoluble product was filtered

off and purified by recrystallization from methanol yielding 45 mg (91%) of a red solid.

^{1}H-NMR (400 MHz, Methanol-d4): δ 8.71 (d, J = 2.4 Hz, 2H), 8.43 (dd, J = 9.0, 2.5 Hz, 2H), 7.90 (d, J = 9.0 Hz, 2H), 7.04 (s, 2H).

^{13}C-NMR (100 MHz, Methanol-d4): δ 180.2, 164.2, 160.3, 157.9, 149.3, 126.7, 124.2, 121.5, 120.3, 111.1.

HR-MS (ESI, [M+Na]$^+$): Calcd. for C$_{20}$H$_9$N$_2$O$_8$Na : 451.0154 ; Found: 451.0149.

### 2.5.6.3 Synthesis of MAC and PAC

Methyl 5-hydroxy-4-oxo-4H-chromene-2-carboxylate (7) 2,6-

Dihydroxyacetophenone (1.50 g, 9.90 mmol) and dimethyloxalate (5.80 g, 49.3 mmol) were dissolved in 0.5 M MeONa/MeOH (100 mL) and heated at reflux overnight. The solvent was removed in vacuo and the slurry was dissolved in water (100 mL) and subsequently acidified with

concentrated HCl. The precipitate was filtered off and dissolved in MeOH (50 mL) and concentrated HCl (10 mL). This solution was heated at reflux for 2 h after which the crude product was purified by flash chromatography (Silicagel, 40-63 μm, pentane/AcOEt, 9:1, v/v) yielding 762 mg (33%) of a yellow powder.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.61 (appt, J=8.4 Hz, 1H), 7.03-7.06 (m, 2H), 6.85 (d, J=8.3 Hz, 1H), 4.02 (s, 3H). ^{1}H-NMR spectrum in agreement with published data.[28]

1-Methyl-3-nitrosobenzene (8a) 3-Methylaniline (708 mg, 6.61 mmol) was dissolved in DCM (20 mL), a solution of oxone (8.10g, 13.2 mmol) in water (80 mL) was added and the resulting biphasic mixture was stirred at room temperature for 30 min. The organic layer was separated and the aqueous layer was extracted twice with DCM. The combined organic layers were washed with 1 M aq. HCl, saturated NaHCO$_3$ and brine and dried (MgSO$_4$). The crude product was purified by flash chromatography (Silicagel, 40-63 μm, pentane/AcOEt, 4:1, v/v), yielding 430 mg (54%) of a light green solid.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.77 (d, J=6.4 Hz, 1H), 7.63 (s, 1H), 7.48-7.54 (m, 2H), 2.50 (s, 3H). ^{1}H-NMR spectrum in agreement with published data.[42]

1-Methyl-4-nitrosobenzene (8b) 4-Methylaniline (5.00 g, 33.1 mmol) was dissolved in DCM (100 mL), a solution of oxone (40.7 g, 66.2 mmol) in water (400 mL) was added and the resulting biphasic mixture was stirred at room temperature for 30 min. The organic layer was separated and the aqueous layer was extracted twice with DCM. The combined organic layers were washed with 1 M aq. HCl, saturated NaHCO$_3$ and brine and dried (MgSO$_4$). Evaporation of the solvent yielded 2.34 g (59%) of a light green solid.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.81 (d, J=8.2 Hz, 2H), 7.39 (d, J=8.0 Hz, 2H), 2.44 (s, 3H). ^{1}H-NMR spectrum in agreement with published data.[43]

3,3'-Dimethylazobenzene (9a) Compound **8a** (500 mg, 4.13 mmol) and 3-methylaniline (369 mg, 3.44 mmol) were dissolved in glacial acetic acid (33 mL) and the mixture was stirred overnight. The solution was diluted with water and extracted with ethyl acetate. The organic phase was washed four times with water and once with brine and dried (MgSO$_4$). The crude product was filtered through silica yielding 400 mg (55%) of an orange solid.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.70-7.74 (m, 4H), 7.41 (appt, J=8.0 Hz, 2H), 7.29 (d, J=7.6 Hz, 2H), 2.46 (s, 6H). ^{1}H-NMR spectrum in agreement with published data.[44]

4,4'-Dimethylazobenzene (9b)   Compound **8b** (300 mg, 2.48 mmol) and 4-methylaniline (292 mg, 2.73 mmol) were dissolved in glacial acetic acid (20 mL) and stirred overnight. The solution was diluted with water and extracted with ethyl acetate. The organic phase was washed four times with water and once with brine and dried (MgSO$_4$). The crude product was purified by flash chromatography (Silicagel, 40-63 µm, pentane/Et$_2$O, 9:1, v/v) yielding 450 mg (86%) of an orange solid.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.81 (d, J=8.4 Hz, 4H), 7.30 (d, J=8.4 Hz, 4H), 2.43 (s, 6H). ^{1}H-NMR spectrum in agreement with published data.[45]

3,3'-Bis(bromomethyl)azobenzene (10a)   To a solution of compound **9a** (1.30 g, 6.18 mmol) in 60 mL of CCl$_4$ was added NBS (2.50 g, 14.2 mmol) and AIBN (80 mg, 0.48 mmol). The resultant solution was stirred overnight at 70°C, then filtered and the filtrate was washed with hot water and brine and dried (MgSO$_4$). After evaporation the product was recrystallized from acetonitrile yielding 800 mg (35%) of an orange solid. Mp. 140-141 °C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.95 (m, 2H), 7.87 (m, 2H), 7.52 (m, 4H), 4.59 (s, 4H). ^{1}H-NMR spectrum in agreement with published data.[44]

4,4'-Bis(bromomethyl)azobenzene (10b)   To a solution of compound **9b** (300 mg, 1.43 mmol) in 20 mL of CCl$_4$ was added NBS (584 mg, 3.30 mmol) and AIBN (18 mg, 0.10 mmol). The resultant solution was stirred overnight at 70 °C, then filtered and the filtrate was washed with hot water and brine and dried (MgSO$_4$). After evaporation of the solvent, the product was recrystallized from acetonitrile yielding 220 mg (42%) of an orange solid. Mp. 183-185 °C.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.89 (d, J=8.4 Hz, 4H), 7.54 (d, J=8.4 Hz, 4H), 4.56 (s, 4H). ^{1}H-NMR spectrum in agreement with published data.[45]

(E)-dimethyl5,5'-(((diazene-1,2-diylbis(3,1-phenylene))bis(methylene))bis(oxy))bis(4-oxo-4H-chromene-2-carboxylate) (11a)

To a solution of compounds **7** (638 mg, 2.73 mmol) and **10a** (400 mg, 1.09 mmol) in 80 mL acetonitrile was added K_2CO_3 (451.93 mg, 3.27 mmol) and the resulting mixture was stirred overnight at 65 °C. The solution was concentrated in vacuo and the crude product was purified using flash chromatography (Silicagel, 40-63 μm, DCM/Methanol, 95:5, v/v) yielding 520 mg (70%) of a light orange solid.

^{1}H-NMR (400 MHz, CDCl$_3$): δ 8,06 (s, 2H), 7.90-7.85 (m, 4H), 7.56-7.61 (m, 4H), 7.18 (d, J = 8.5 Hz, 2H), 7.02 (s, 2H), 6.91 (d, J = 8.3 Hz, 2H), 5.38 (s, 4H), 4.00 (s, 6H).

^{13}C NMR (100 MHz, CDCl$_3$): δ 177.6, 161.1, 158.4, 158.0, 152.7, 150.1, 137.5, 134.7, 129.7, 129.4, 122.6, 120.7, 116.7, 113.8, 111.1, 108.9, 70.6, 53.4.

HR-MS (ESI, [M+H]$^+$): Calcd. for $C_{36}H_{27}N_2O_{10}$: 647.1660 ; Found: 647.1603.

(E)-dimethyl5,5'-(((diazene-1,2-diylbis(4,1-phenylene))bis(methylene))bis(oxy))bis(4-oxo-4H-chromene-2-carboxylate) (11b)

To a solution of compounds **7** (100 mg, 0.45 mmol) and **10b** (75.8 mg, 0.21 mmol) in acetonitrile (25 mL) was added


Cs_2CO_3 (201 mg, 0.62 mmol) and the resulting mixture was stirred at 65 °C for 3 h. The solution was concentrated in vacuo and the residue was dissolved in DCM, washed with 1 M aq. HCl, saturated NaHCO$_3$ and brine and dried (MgSO$_4$). After evaporation the product was recrystallized from DCM yielding 27 mg of a light orange solid. Mp. 235-237 °C (dec.).

^{1}H-NMR (400 MHz, CDCl$_3$): δ 7.96 (d, J = 8.0 Hz, 4H), 7.76 (d, J = 8.1 Hz, 4H), 7.58 (t, J = 8.0, 2H), 7.18 (d, J = 8.2 Hz, 2H), 7.02 (s, 2H), 6.90 (d, J = 8.3 Hz, 2H), 5.36 (s, 4H), 4.00 (s, 6H).

^{13}C-NMR (100 MHz, CDCl$_3$): δ 177.7, 161.1, 158.4, 158.0, 152.2, 150.1, 139.3, 134.6, 127.2, 123.2, 116.6, 113.8, 111.1, 108.7, 70.5, 53.4.

HR-MS (ESI, [M+H]$^+$): Calcd. for C$_{36}$H$_{27}$N$_2$O10: 669.1485 ; Found: 669.1480.

Sodium(*E*)-5,5'-(((diazene-1,2-diylbis(3,1-phenylene))bis(methylene)) bis(oxy))bis(4-oxo-4H-chromene-2-carboxylate) (12a) (MAC)

To a solution of compound **11a** (100 mg, 0.15 mmol) in ethanol (5 mL) was added aq. NaOH (2.5 M, 186 µL) dropwise at 0°C. The reaction mixture was heated at reflux for 2 h after which the insoluble product was filtered off yielding 85 mg (86%) of an orange solid.

^{1}H-NMR (400 MHz, Methanol-d$_4$): δ 8.12 (s, 2H), 7.86 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 7.63 (m, 4H), 7.26 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 6.88 (s, 2H), 5.42 (s, 4H).

^{13}C-NMR (100 MHz, Methanol-d$_4$): δ 180.4, 164.7, 158.3, 158.1, 157.9, 152.7, 138.3, 134.5, 129.1, 121.2, 113.8, 112.5, 110.9, 108.5, 69.9.

HR-MS (ESI, [M+Na]$^+$)**:** Calcd. for C$_{34}$H$_{22}$N$_2$O$_{10}$Na: 641.1167 ; Found: 641.1140.

Sodium (*E*)-5,5'-(((diazene-1,2-diylbis(4,1-phenylene))bis(methylene)) bis(oxy))bis(4-oxo-4H-chromene-2-carboxylate) (12b) (PAC)

To a solution of compound **11b** (25 mg, 0.04 mmol) in ethanol (3 mL) was added aq. NaOH (2.5 M, 50 µL) dropwise at 0 °C. The reaction mixture was heated at reflux for 2 h after which the insoluble product was filtered off yielding 23 mg (91%) of an orange solid.

^{1}H-NMR (400 MHz, Methanol-d$_4$): δ 7.96 (d, J = 8.3 Hz, 4H), 7.80 (d, J = 8.2 Hz, 4H), 7.67 (t, J = 8.4 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.3 Hz, 2H), 6.89 (s, 2H), 5.41 (s, 4H).

^{13}C-NMR (100 MHz, Methanol-d$_4$): δ 180.3, 164.6, 158.3, 158.1, 158.0, 155.8, 152.1, 140.2, 134.4, 127.3, 122.5, 112.5, 110.9, 108.4, 69.8.

HR-MS (ESI, [M+Na]$^+$)**:** Calcd. for $C_{34}H_{22}N_2O_{10}Na$: 641.1167 ; Found: 641.1155.

2.6   References

(1)   Sly, R. M. *Ann. Allergy Asthma Immunol.* **1999**, *28*, 233.
(2)   Ghouri, N.; Hippisley-Cox, J.; Newton, J.; Sheikh, A. *J. R. Soc. Med.* **2008**, *101*, 466.
(3)   Horak, F. *Expert Opin. Invest. Drugs* **2011**, *20*, 981.
(4)   Di Capite, J. L.; Bates, G. J.; Parekh, A. B. *Curr. Opin. Allergy Clin. Immunol.* **2011**, *11*, 33.
(5)   Mandhane, S. N.; Shah, J. H.; Thennati, R. *Int. Immunopharmacol.* **2011**, *11*, 1646.
(6)   Barnes, P. J. *Br. J. Pharmacol.* **2006**, *147*, S297.
(7)   McDonough, A. K.; Curtis, J. R.; Saag, K. G. *Curr. Opin. Rheumatol.* **2008**, *20*, 131.
(8)   Schacke, H.; Docke, W. D.; Asadullah, K. *Pharmacol. Ther.* **2002**, *96*, 23.
(9)   Mullane, K. *Biochem. Pharmacol.* **2011**, *82*, 586.
(10)   Spataro, A. C.; Bosmann, H. B. *Biochem. Pharmacol.* **1976**, *25*, 505.
(11)   Schwartz, L. B.; Austen, K. F. *J. Invest. Dermatol.* **1980**, *74*, 349.
(12)   Metcalfe, D. D.; Baram, D.; Mekori, Y. A. *Physiol. Rev.* **1997**, *77*, 1033.
(13)   Klemm, S.; Ruland, J. *Immunobiology* **2006**, *211*, 815.
(14)   Mazurek, N.; Bashkin, P.; Loyter, A.; Pecht, I. *Proc. Natl. Acad. Sci. U.S.A.* **1983**, *80*, 6014.
(15)   Mazurek, N.; Berger, G.; Pecht, I. *Nature* **1980**, *286*, 722.
(16)   Foreman, J. C.; Garland, L. G. *Brit. Med. J.* **1976**, *1*, 820.
(17)   Howell, J. B. L.; Altounyan, R. E. C. *Lancet* **1967**, *290*, 539.
(18)   Cairns, H.; Cox, J. S. G.; Minshull, R.; Fitzmaur, C.; Lord, G. H.; Lee, T. B.; King, J.; Johnson, P. B.; Hunter, D. *J. Med. Chem.* **1972**, *15*, 583.
(19)   Portoghese, P. S.; Nagase, H.; MaloneyHuss, K. E.; Lin, C.-E.; Takemori, A. E. *J. Med. Chem.* **1991**, *34*, 1715.
(20)   Beharry, A. A.; Woolley, G. A. *Chem. Soc. Rev.* **2011**, *40*, 4422.
(21)   Vomasta, D.; Högner, C.; Branda, N. R.; König, B. *Angew. Chem., Int. Ed.* **2008**, *40*, 7644.
(22)   Stein, M.; Middendorp, S. J.; Carta, V.; Pejo, E.; Raines, D. E.; Forman, S. A.; Sigel, E.; Trauner, D. *Angew. Chem., Int. Ed.* **2001**, *51*, 10500.
(23)   Mendonça, C. R.; Balogh, D. T.; De Boni, L.; dos Santos, D. S.; Zucolotto, V.; Oliveira, O. N.; Feringa, B. L.; Browne, W. R. *Molecular Switches*; 2nd, Ed.; 2011.

(24)   Portoghese, P. S. *Trends Pharmacol. Sci.* **1989**, *10*, 230.

(25)   Portoghese, P. S. *J. Med. Chem.* **2001**, *44*, 2259.

(26)   Walenzyk, T.; Carola, C.; Buchholz, H.; König, B. *Tetrahedron* **2005**, *61*, 7366.

(27)   Barker, G.; Ellis, G. P. *J. Chem. Soc., C* **1970**, 2230.

(28)   Wu, L.; Lal, J.; Simon, K. A.; Burton, E. A.; Luk, Y. Y. *J. Am. Chem. Soc.* **2009**, *131*, 7430.

(29)   Bandara, H. M. D.; Burdette, S. C. *Chem. Soc. Rev.* **2012**, *41*, 1809.

(30)   Kirshenbaum, A. S.; Akin, C.; Wu, Y. L.; Rottem, M.; Goff, J. P.; Beaven, M. A.; Rao, V. K.; Metcalfe, D. D. *Leuk. Res.* **2003**, *27*, 677.

(31)   Passante, E.; Ehrhardt, C.; Sheridan, H.; Frankish, N. *Inflamm. Res.* **2009**, *58*, 611.

(32)   Schwartz, L. B.; Austen, K. F.; Wasserman, S. I. *J. Immunol.* **1979**, *123*, 1445.

(33)   Paton, W. D. M. *Brit. J. Pharm.* **1951**, *6*, 499.

(34)   Shore, P. A.; Burkhalter, A.; Cohn, V. H. *J. Pharmacol. Exp. Ther.* **1959**, *127*, 182.

(35)   Khandwala, A.; Vaninwegen, R.; Coutts, S.; Dallymeade, V.; Youssefyeh, R. D. *Int. J. Immunopharmacol.* **1983**, *5*, 491.

(36)   Norris, A. A.; Alton, E. W. F. W. *Clin. Exp. Allergy* **1996**, *26*, 250.

(37)   Yang, Y. H.; Lu, J. Y. L.; Wu, X. S.; Summer, S.; Whoriskey, J.; Saris, C.; Reagan, J. D. *Pharmacology* **2010**, *86*, 1.

(38)   Samanta, S.; Qin, C.; Lough, A. J.; Woolley, G. A. *Angew. Chem., Int. Ed.* **2012**, *51*, 6452.

(39)   Szymanski, W.; Wu, B.; Poloni, C.; Janssen, D. B.; Feringa, B. L. *Angew. Chem., Int. Ed.* **2013**, *52*, 2068.

(40)   Bléger, D.; Schwarz, J.; Brouwer, A. M.; Hecht, S. *J. Am. Chem. Soc.* **2012**, *134*, 20597.

(41)   Szymanski, W.; Beierle, J. M.; Kistemaker, H.; Velema, W. A.; Feringa, B. L. *Chem. Rev.* **2013**, *113*, 6114.

(42)   Zhu, D.; Lu, M.; Chua, P. J.; Tan, B.; Wang, F.; Yang, X.; Zhong, G. *Org. Lett.* **2008**, *10*, 4585.

(43)   Sakamoto, R.; Murata, M.; Kume, S.; Sampei, H.; Sugimoto, M.; Nishihara, H. *Chem. Commun.* **2005**, 1215.

(44)   Jousselme, B.; Blanchard, P.; Gallego-Planas, N.; Levillain, E.; Delaunay, J.; Allain, M.; Richomme, P.; Roncali, J. *Chem–Eur. J.* **2003**, *9*, 5297.

(45)   Bonardi, F.; London, G.; Nouwen, N.; Feringa, B.; Driessen, A. J. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 7234.